… of the negligible benefit showed by erlotinib[56], tested targeted … patients with metastatic PC
after failure of gemcitabine. Also … gemcitabine plus placebo in advanced pancreatic cancer. J …

… of blocking insulin-like growth factor receptor-1 (IGF-1R) along with epidermal growth factor
receptor and gemcitabine … The combination of cixutumumab (IGF-1R blocker), erlotinib (anti-…

… EGFR (also termed human epidermal growth factor receptor 1 [… in combination with a different
mAb, cixutumumab, was also … , the Phase I study of erlotinib in combination with the dual …

… and sustain tumor cell propogation as well as metastases. … combination with gemcitabine
or gemcitabine plus Erlotinib. … signaling between the epidermal growth factor receptor (EGFR) …

… Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1
signaling in metastatic … of gemcitabine, erlotinib, and cixutumumab versus gemcitabine …

… , erlotinib was approved in combination with gemcitabine for … -Lung 2 phase II trial, in which
129 adenocarcinoma patients … The first drug studied was cixutumumab in patients refractory …

… demonstrate enhanced ligand blockade and anti-tumor activity. … A phase I/II study of erlotinib
in combination with the anti-… shown that signaling through the IGF-1 receptor can overcome …

… Antibody binding to IGF1R inhibits downstream signaling of the … 12 mg/m 2 + gemcitabine
tolerated the drug without side … with cixutumumab in patients with naïve primary metastatic PCa …

… IGF-1R signaling, cixutumumab can sensitize tumor cells to the … tumor models in vivo, IGF-1R
blockade by cixutumumab … mg/kg q3w) with adenocarcinoma of the colon received therapy …

… gemcitabine alone in an independent metastatic pancreatic … Anti-IGF-1R antibody cixutumumab
conjugated to PEGylated … with erlotinib alone in a phase II clinical trial involving NSCLC …